Compare Medtronic PLC (MDT) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Synopsys, Inc. — how do they compare? Medtronic PLC trades at $82.63 (market cap $106.61B), while Synopsys, Inc. trades at $388.45 (market cap $72.47B). The key difference: Medtronic PLC is the larger of the two by market cap, and Medtronic PLC pays a 3.46% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| MDT | SNPS | |
|---|---|---|
Market Cap | $106.61B | $72.47B |
Sector | Health | Technology |
52-Week High | $105.35 | $645.59 |
52-Week Low | $73.75 | $378.46 |
Enterprise Value | $125.36B | $80.82B |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $82.35, down 1.02% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.39. Revenue grew to $33.54B in 2025, with a net income margin of 13.2%. Recent news highlights the acquisition of SPR and the launch of AI-powered surgical technology, signaling innovation-driven growth.
The outlook for MDT is positive, supported by analyst consensus with a $97.50 price target and 58% buy ratings. Key opportunities include robust cash flow and dividend stability, while risks involve rising debt levels and competitive pressures in medtech. The stock presents a value proposition with a P/E of 22.33, trading below the consensus target.
Synopsys (SNPS) trades at $388.84, up 1.19% on the day, with a bearish technical signal despite recent earnings beats. The stock faces headwinds from semiconductor sector volatility but maintains strong analyst support with an 82.76% buy rating. Recent news highlights the company's strategic pivot toward AI design tools and margin expansion following its Ansys integration, positioning it as a key enabler in the chip design ecosystem despite near-term price pressure.
Outlook remains positive long-term due to SNPS's dominant EDA market position and AI-driven growth opportunities, though investors face risks from cyclical semiconductor demand and integration execution. The consensus price target of $559.50 implies significant upside if the company delivers on its AI strategy and margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
